On Friday shares of ImmunoGen, Inc. (NASDAQ:IMGN) closed at $8.25. Company’s sales growth for last 5 years was 16.40%.On March 20, 2015, ImmunoGen, Inc. (NASDAQ:IMGN) entered into a right-to-test agreement with Takeda Pharmaceutical Company Limited through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. The agreement provides Takeda with the right to (a) take exclusive options, with certain restrictions, to individual targets selected by Takeda for specified option periods, (b) test our antibody-drug conjugate (ADC) technology with Takeda’s antibodies directed to the targets optioned under a right-to-test, or research, license, and (c) take exclusive licenses to use our ADC technology to develop and commercialize products for up to two optioned targets on terms specified in this right-to-test agreement.
Repligen Corporation (NASDAQ:RGEN) in last trading activity increased 7.00% to close at $30.57. Company weekly performance is -5.41% while its quarterly performance stands at 54.08%. Repligen Corporation (NASDAQ:RGEN) is -10.48% away from its 52 week high. On March 16, Repligen Corp. (NASDAQ:RGEN) reported a fourth quarter loss of $0.01 per share, compared to the profit of $0.10 per share last year. Analysts expected EPS of $0.04.
On Friday shares of AT&T, Inc. (NYSE:T) closed at $32.75. Company’s sales growth for last 5 years was 1.60% and EPS growth for next 5 years is recorded as 4.68%. The board of directors of AT&T Inc (NYSE:T) declared a quarterly dividend of $0.47 a share on the company’s common shares. The dividend is payable on May 1, 2015, to stockholders of record at the close of business on April 10, 2015.
AeroVironment, Inc. (NASDAQ:AVAV) has 14.41% insider ownership while its institutional ownership stands at 62.00%. In last trading activity company’s stock closed at $26.53. On March 25, it was reported that, AeroVironment Inc. (NASDAQ:AVAV) and Lockheed Martin are set to begin production of drones in India for overseas sales, Bloomberg reported, citing two Indian defence officials with knowledge of the matter.
On last trading day TherapeuticsMD, Inc. (NYSEMKT:TXMD) increased 3.09% to close at $6.00. Its volatility for the week is 7.36% while volatility for the month is 6.56%. TXMD’s EPS growth for past 5 years was 47.00%. TherapeuticsMD, Inc. (NYSEMKT:TXMD) monthly performance is 12.36%. On March 18, TherapeuticsMD, Inc. (NYSEMKT:TXMD), announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.